Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Psoriasis (Oct 2019)

Posted by Matt Breese on Oct 11, 2019

Find me on:

According to our recent payer coverage analysis for psoriasis (PsO) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for psoriasis treatments shows that under the pharmacy benefit, almost 74% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Psoriasis_3Q2019Data snapshot as of Q3 2019

Trends: In July 2019, the FDA approved Samsung Bioepis Co., Ltd.'s Hadlima (adalimumab-bwwd) for the treatment of plaque psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease and ulcerative colitis.   

To read the full Reality Check on Psoriasis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing